Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 26Lymphoid 6Other hematologic neoplasm 2

Conditions

Multiple Myeloma 4Leukemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Plasma Cell 3Hematologic Neoplasms 3Recurrence 2Lymphoma 2Leukemia, Myeloid, Acute 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 72Cytarabine 61fludarabine phosphate 48venetoclax 42Peripheral Blood Stem Cell Transplantation 37fludarabine 34Busulfan 31Methotrexate 29Cyclosporine 29Mycophenolic Acid 28Filgrastim 27Azacitidine 27Antilymphocyte Serum 26Whole-Body Irradiation 22Etoposide 21Radiotherapy 20Melphalan 20Tacrolimus 19Rituximab 19Dexamethasone 16Methylprednisolone 15Granulocyte Colony-Stimulating Factor 15Decitabine 15Vincristine 14Cord Blood Stem Cell Transplantation 14Doxorubicin 13Clofarabine 11Mitoxantrone 10ibrutinib 9blinatumomab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × carfilzomib × Other hematologic neoplasm × Clear all
NCT02512926 2025-10-15

POE14-01

Stanford University

Phase 1 Completed
4 enrolled
Other hematologic neoplasm

Leukemia, Recurrence

NCT02145403 2022-01-03

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

University of Michigan Rogel Cancer Center

Phase 1/2 Completed
53 enrolled 17 charts
LymphoidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡